Tenaya Therapeutics, INC 8-K filings

Tenaya Therapeutics announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, succeeding Faraz Ali and Tomohiro Higa in interim roles.

Tenaya Therapeutics stockholders approved an amended 2021 Equity Incentive Plan and re-elected three Class II directors at the 2026 Annual Meeting.

Tenaya Therapeutics reported Q1 2026 financial results, highlighting progress in its gene therapy programs for genetic cardiomyopathies and a new research collaboration with Alnylam.

Tenaya Therapeutics has entered a significant collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for cardiovascular disease, potentially worth over $1.1 billion.

Tenaya Therapeutics received a Nasdaq notice for failing to meet the minimum bid price requirement, while also expanding its equity incentive plan to attract new talent.

David Goeddel has voluntarily resigned from Tenaya Therapeutics' Board of Directors, effective January 26, 2026, due to retirement.

Tenaya Therapeutics announced the pricing of an underwritten public offering of 50 million units, each consisting of one common stock share and one warrant, to raise approximately $60 million for pipeline development.

Tenaya Therapeutics announced the FDA lifted the clinical hold on its MyPEAK-1 trial for TN-201 and reported positive interim data from the RIDGE-1 trial for TN-401.

Tenaya Therapeutics announced its third-quarter 2025 financial results and provided updates on its lead gene therapy programs, TN-201 and TN-401, including a clinical hold on MyPEAK-1.

The FDA has placed a clinical hold on Tenaya Therapeutics' MyPEAK-1 trial for TN-201, requesting protocol amendments for patient monitoring and immunosuppression management.

Tenaya Therapeutics announced positive clinical trial advancements for its gene therapies TN-201 and TN-401, alongside a reduced net loss and extended cash runway into the second half of 2026.

Tenaya Therapeutics, Inc. announced the successful re-election of its Class I directors and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm at its annual meeting held on May 28, 2025.

Tenaya Therapeutics reports encouraging interim data from its TN-201 clinical trial, highlights unmet needs in ARVC, and extends its cash runway into the second half of 2026.

Tenaya Therapeutics receives notification from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share, potentially leading to delisting.

Tenaya Therapeutics is implementing a restructuring plan, including workforce reduction, to focus on key programs and extend its cash runway into the second half of 2026.

Tenaya Therapeutics announces its Q4 and full year 2024 financial results, highlighting clinical trial progress and a recent financing round extending its cash runway into mid-2026.

Tenaya Therapeutics has announced the pricing of a public offering of 75,000,000 units at $0.70 per unit, expecting gross proceeds of $52.5 million.

Tenaya Therapeutics announces the appointment of Tomohiro Higa as Interim Principal Accounting Officer and the repricing of CEO Faraz Ali's underwater stock options to improve retention and motivation.

Tenaya Therapeutics has repriced underwater stock options for employees to align with the current market price and incentivize retention.

Tenaya Therapeutics reported positive early data from its MyPEAK-1 clinical trial, showing that TN-201 gene therapy was well-tolerated and demonstrated early signs of efficacy in patients with MYBPC3-associated hypertrophic cardiomyopathy.

Tenaya Therapeutics announces the resignation of its Senior Vice President, Accounting and Financial Operations and Interim Principal Accounting Officer, effective December 16, 2024.

Tenaya Therapeutics reported positive safety updates and progress in their gene therapy trials, along with their third quarter 2024 financial results.

Tenaya Therapeutics has reclassified a board member to evenly distribute membership and adopted a new inducement equity incentive plan.

Tenaya Therapeutics reported its second quarter 2024 financial results, highlighted by a new credit facility, progress in clinical trials, and key personnel changes.

Tenaya Therapeutics' Chief Financial and Business Officer, Leone Patterson, has resigned to pursue another opportunity, with her departure effective August 14, 2024.

Jin-Long Chen has resigned from the board of directors of Tenaya Therapeutics, effective June 25, 2024.

Tenaya Therapeutics held its annual meeting on May 30, 2024, electing three Class III directors and ratifying Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2024.

Tenaya Therapeutics reported its first quarter 2024 financial results, provided updates on its clinical programs, and announced a workforce reduction as part of cost containment measures.

Tenaya Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs, including the expectation of initial data from the MyPeak-1 trial in the second half of 2024.

Tenaya Therapeutics has priced an underwritten offering to raise approximately $50 million through the sale of common stock and pre-funded warrants.